Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.
Sanofi, Johnson & Johnson, Eli Lilly and Bristol Myers Squibb have each filed complaints after facing federal opposition to ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
It's a special delivery for Pocono Services for Families and Children at the Mountain Center in Tobyhanna. Bag after bag of ...
Sanofi has filed a lawsuit against the Biden administration over payment terms in a federal drug discount program.
HRSA warns Sanofi that its credit model for 340B drugs violates the statute, demanding immediate cessation to avoid penalties ...
Sanofi and Regeneron are in the process of testing out blockbuster biologic Dupixent in the indication, for one, and ...
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...
GlobalData on MSN3d
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trialSanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback